Articles - 3bce mentioned but not cited (12)
- Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, Banjade S, Pal A, Bornmann WG, Lemmon MA, Cole PA, Leahy DJ. Structure 16 460-467 (2008)
- Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S. J. Biol. Chem. 286 18756-18765 (2011)
- Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Sci Signal 7 ra114 (2014)
- Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. Shih AJ, Telesco SE, Choi SH, Lemmon MA, Radhakrishnan R. Biochem. J. 436 241-251 (2011)
- Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions. James KA, Verkhivker GM. PLoS ONE 9 e113488 (2014)
- Characterizing monoclonal antibody structure by carboxyl group footprinting. Kaur P, Tomechko SE, Kiselar J, Shi W, Deperalta G, Wecksler AT, Gokulrangan G, Ling V, Chance MR. MAbs 7 540-552 (2015)
- Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Zhang H, Shen W, Rempel D, Monsey J, Vidavsky I, Gross ML, Bose R. Mol. Cell Proteomics 10 M110.005678 (2011)
- Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Dixit A, Verkhivker GM. Comput Math Methods Med 2014 653487 (2014)
- SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase. Knittle AM, Helkkula M, Johnson MS, Sundvall M, Elenius K. J. Biol. Chem. 292 19890-19904 (2017)
- Characterizing monoclonal antibody structure by carbodiimide/GEE footprinting. Kaur P, Tomechko S, Kiselar J, Shi W, Deperalta G, Wecksler AT, Gokulrangan G, Ling V, Chance MR. MAbs 6 1486-1499 (2014)
- Conformational transition paths harbor structures useful for aiding drug discovery and understanding enzymatic mechanisms in protein kinases. Wong CF. Protein Sci. 25 192-203 (2016)
- An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Chakroborty D, Ojala VK, Knittle AM, Drexler J, Tamirat MZ, Ruzicka R, Bosch K, Woertl J, Schmittner S, Elo LL, Johnson MS, Kurppa KJ, Solca F, Elenius K. Cancer Res Commun 2 10-27 (2022)
Reviews citing this publication (29)
- Cell signaling by receptor tyrosine kinases. Lemmon MA, Schlessinger J. Cell 141 1117-1134 (2010)
- FDA-approved small-molecule kinase inhibitors. Wu P, Nielsen TE, Clausen MH. Trends Pharmacol. Sci. 36 422-439 (2015)
- The structural basis for control of eukaryotic protein kinases. Endicott JA, Noble ME, Johnson LN. Annu. Rev. Biochem. 81 587-613 (2012)
- Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Mol. Cell 42 9-22 (2011)
- Ligand-induced ErbB receptor dimerization. Lemmon MA. Exp. Cell Res. 315 638-648 (2009)
- The EGFR family: not so prototypical receptor tyrosine kinases. Lemmon MA, Schlessinger J, Ferguson KM. Cold Spring Harb Perspect Biol 6 a020768 (2014)
- ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. Stern DF. J Mammary Gland Biol Neoplasia 13 215-223 (2008)
- EGFR-mutated lung cancer: a paradigm of molecular oncology. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. Oncotarget 1 497-514 (2010)
- A structural perspective on the regulation of the epidermal growth factor receptor. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. Annu. Rev. Biochem. 84 739-764 (2015)
- Regulation of the catalytic activity of the EGF receptor. Endres NF, Engel K, Das R, Kovacs E, Kuriyan J. Curr. Opin. Struct. Biol. 21 777-784 (2011)
- Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. de Bartolomeis A, Latte G, Tomasetti C, Iasevoli F. Mol. Neurobiol. 49 484-511 (2014)
- ErbB receptors in the biology and pathology of the aerodigestive tract. Morgan S, Grandis JR. Exp. Cell Res. 315 572-582 (2009)
- The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Bose R, Zhang X. Exp. Cell Res. 315 649-658 (2009)
- αC helix displacement as a general approach for allosteric modulation of protein kinases. Palmieri L, Rastelli G. Drug Discov. Today 18 407-414 (2013)
- Structural Basis for the Non-catalytic Functions of Protein Kinases. Kung JE, Jura N. Structure 24 7-24 (2016)
- Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression. Bennett M. Aust N Z J Psychiatry 43 711-721 (2009)
- Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Schroeder RL, Stevens CL, Sridhar J. Molecules 19 15196-15212 (2014)
- Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Black LE, Longo JF, Carroll SL. Am J Pathol 189 1898-1912 (2019)
- Oncogenes in melanoma: an update. Kunz M. Eur. J. Cell Biol. 93 1-10 (2014)
- Molecular mechanisms of asymmetric RAF dimer activation. Jambrina PG, Bohuszewicz O, Buchete NV, Kolch W, Rosta E. Biochem. Soc. Trans. 42 784-790 (2014)
- Prospects for pharmacological targeting of pseudokinases. Kung JE, Jura N. Nat Rev Drug Discov 18 501-526 (2019)
- The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. Kennedy SP, Hastings JF, Han JZ, Croucher DR. Front Cell Dev Biol 4 88 (2016)
- Competing Endogenous RNA Networks in Glioma. Cen L, Liu R, Liu W, Li Q, Cui H. Front Genet 12 675498 (2021)
- More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. Diwanji D, Thaker T, Jura N. IUBMB Life 71 706-720 (2019)
- Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles. Zanetti-Domingues LC, Bonner SE, Martin-Fernandez ML, Huber V. Cells 9 E2505 (2020)
- The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications. Guo W, Vandoorne T, Steyaert J, Staats KA, Van Den Bosch L. Brain 143 1651-1673 (2020)
- Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Molecules 26 6677 (2021)
- A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors. El-Gamal MI, Mewafi NH, Abdelmotteleb NE, Emara MA, Tarazi H, Sbenati RM, Madkour MM, Zaraei SO, Shahin AI, Anbar HS. Molecules 26 7376 (2021)
- THE MAKING OF A FOOTPRINT IN PROTEIN FOOTPRINTING: A REVIEW IN HONOR OF MICHAEL L. GROSS. McKenzie-Coe A, Shortt R, Jones LM. Mass Spectrom Rev (2020)
Articles citing this publication (66)
- Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J. Cell 137 1293-1307 (2009)
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. Proc. Natl. Acad. Sci. U.S.A. 107 7692-7697 (2010)
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y. Nat. Genet. 41 1127-1132 (2009)
- The juxtamembrane region of the EGF receptor functions as an activation domain. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G. Mol. Cell 34 641-651 (2009)
- Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Proc. Natl. Acad. Sci. U.S.A. 106 21608-21613 (2009)
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DWY, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, Farahani H, Shumansky K, Kingsbury Z, Humphray S, Bentley D, Shah SP, Wallis M, Rosenfeld N, Caldas C. Nat Commun 6 8760 (2015)
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE. J. Clin. Invest. 123 2155-2168 (2013)
- Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Alvarado D, Klein DE, Lemmon MA. Cell 142 568-579 (2010)
- Deciphering the structural basis of eukaryotic protein kinase regulation. Meharena HS, Chang P, Keshwani MM, Oruganty K, Nene AK, Kannan N, Taylor SS, Kornev AP. PLoS Biol. 11 e1001680 (2013)
- Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Sci Transl Med 2 16ra7 (2010)
- Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. PLoS ONE 6 e26760 (2011)
- Cytohesins are cytoplasmic ErbB receptor activators. Bill A, Schmitz A, Albertoni B, Song JN, Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert L, Schreiber A, Chatterjee S, Thomas RK, Ullrich RT, Lang T, Famulok M. Cell 143 201-211 (2010)
- Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Proc. Natl. Acad. Sci. U.S.A. 110 E3595-604 (2013)
- Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. Dixit A, Verkhivker GM. PLoS Comput. Biol. 7 e1002179 (2011)
- Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. Monsey J, Shen W, Schlesinger P, Bose R. J. Biol. Chem. 285 7035-7044 (2010)
- Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Bezler M, Hengstler JG, Ullrich A. Mol Oncol 6 516-529 (2012)
- Molecular basis for multimerization in the activation of the epidermal growth factor receptor. Huang Y, Bharill S, Karandur D, Peterson SM, Marita M, Shi X, Kaliszewski MJ, Smith AW, Isacoff EY, Kuriyan J. Elife 5 (2016)
- Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. Tvorogov D, Sundvall M, Kurppa K, Hollmén M, Repo S, Johnson MS, Elenius K. J. Biol. Chem. 284 5582-5591 (2009)
- Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. Macdonald-Obermann JL, Pike LJ. J. Biol. Chem. 289 26178-26188 (2014)
- In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Qiu C, Tarrant MK, Boronina T, Longo PA, Kavran JM, Cole RN, Cole PA, Leahy DJ. Biochemistry 48 6624-6632 (2009)
- Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. Kästner J, Loeffler HH, Roberts SK, Martin-Fernandez ML, Winn MD. J. Struct. Biol. 167 117-128 (2009)
- EGFR juxtamembrane domain, membranes, and calmodulin: kinetics of their interaction. Sengupta P, Bosis E, Nachliel E, Gutman M, Smith SO, Mihályné G, Zaitseva I, McLaughlin S. Biophys. J. 96 4887-4895 (2009)
- Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study. Telesco SE, Radhakrishnan R. Biophys. J. 96 2321-2334 (2009)
- Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Masica DL, Karchin R. Cancer Res. 73 1699-1708 (2013)
- Activating ERBB4 mutations in non-small cell lung cancer. Kurppa KJ, Denessiouk K, Johnson MS, Elenius K. Oncogene 35 1283-1291 (2016)
- Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R. J. Biol. Chem. 288 25254-25264 (2013)
- High-throughput sequencing of the melanoma genome. Kunz M, Dannemann M, Kelso J. Exp. Dermatol. 22 10-17 (2013)
- Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL, Adak S, Landgraf R, Piwnica-Worms D, Pike LJ. J. Biol. Chem. 288 30773-30784 (2013)
- Geldanamycin selectively targets the nascent form of ERBB3 for degradation. Gerbin CS, Landgraf R. Cell Stress Chaperones 15 529-544 (2010)
- Comparative analysis of mutant tyrosine kinase chemical rescue. Muratore KE, Seeliger MA, Wang Z, Fomina D, Neiswinger J, Havranek JJ, Baker D, Kuriyan J, Cole PA. Biochemistry 48 3378-3386 (2009)
- Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing. Shih AJ, Purvis J, Radhakrishnan R. Mol Biosyst 4 1151-1159 (2008)
- Prognostic value of ERBB4 expression in patients with triple negative breast cancer. Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im YH. BMC Cancer 16 138 (2016)
- The PAKs come of age: Celebrating 18 years of discovery. Field J, Manser E. Cell Logist 2 54-58 (2012)
- Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. Shih AJ, Telesco SE, Radhakrishnan R. Cancers (Basel) 3 1195-1231 (2011)
- EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N. Proc. Natl. Acad. Sci. U.S.A. 114 E2836-E2845 (2017)
- Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry. Ward MD, Leahy DJ. J. Biol. Chem. 290 1570-1579 (2015)
- Co-conserved features associated with cis regulation of ErbB tyrosine kinases. Mirza A, Mustafa M, Talevich E, Kannan N. PLoS ONE 5 e14310 (2010)
- The Nudix hydrolase CDP-chase, a CDP-choline pyrophosphatase, is an asymmetric dimer with two distinct enzymatic activities. Duong-Ly KC, Gabelli SB, Xu W, Dunn CA, Schoeffield AJ, Bessman MJ, Amzel LM. J. Bacteriol. 193 3175-3185 (2011)
- Cation-π interactions in protein-ligand binding: theory and data-mining reveal different roles for lysine and arginine. Kumar K, Woo SM, Siu T, Cortopassi WA, Duarte F, Paton RS. Chem Sci 9 2655-2665 (2018)
- Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3. Li WW, Chen JJ, Zheng RL, Zhang WQ, Cao ZX, Yang LL, Qing XY, Zhou LX, Yang L, Yu LD, Chen LJ, Wei YQ, Yang SY. ChemMedChem 5 513-516 (2010)
- A fluorescent reporter of ATP binding-competent receptor kinases. Sicard R, Dhuguru J, Liu W, Patel N, Landgraf R, Wilson JN. Bioorg. Med. Chem. Lett. 22 5532-5535 (2012)
- Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants. Fan YX, Wong L, Marino MP, Ou W, Shen Y, Wu WJ, Wong KK, Reiser J, Johnson GR. J. Biol. Chem. 288 16895-16904 (2013)
- Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field. Franco-Gonzalez JF, Ramos J, Cruz VL, Martinez-Salazar J. J. Comput. Aided Mol. Des. 28 1093-1107 (2014)
- Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype. Telesco SE, Vadigepalli R, Radhakrishnan R. Biotechnol J 8 1452-1464 (2013)
- Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. Telesco SE, Shih A, Liu Y, Radhakrishnan R. Cancer Res J (N Y N Y) 4 1-35 (2011)
- Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L. Drug Des Devel Ther 9 3837-3851 (2015)
- ProtCID: a data resource for structural information on protein interactions. Xu Q, Dunbrack RL. Nat Commun 11 711 (2020)
- Homo- and Heteroassociations Drive Activation of ErbB3. Váradi T, Schneider M, Sevcsik E, Kiesenhofer D, Baumgart F, Batta G, Kovács T, Platzer R, Huppa JB, Szöllősi J, Schütz GJ, Brameshuber M, Nagy P. Biophys J 117 1935-1947 (2019)
- Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy. Sahu A, Patra PK, Yadav MK, Varma M. J. Recept. Signal Transduct. Res. 37 470-480 (2017)
- Novel Small Molecules against Two Binding Sites of Wnt2 Protein as potential Drug Candidates for Colorectal Cancer: A Structure Based Virtual Screening Approach. Kalhor H, Rahimi H, Akbari Eidgahi MR, Teimoori-Toolabi L. Iran J Pharm Res 19 160-174 (2020)
- Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors. Sun HP, Zhu J, Chen FH, You QD. Mol Inform 30 579-592 (2011)
- Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Cell Rep 38 110291 (2022)
- Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. Kennedy SP, Han JZR, Portman N, Nobis M, Hastings JF, Murphy KJ, Latham SL, Cadell AL, Miladinovic D, Marriott GR, O'Donnell YEI, Shearer RF, Williams JT, Munoz AG, Cox TR, Watkins DN, Saunders DN, Timpson P, Lim E, Kolch W, Croucher DR. Breast Cancer Res. 21 43 (2019)
- Comment A trigger squeezed. Eigenbrot C. Structure 16 332-334 (2008)
- Activating HER3 mutations in breast cancer. Mishra R, Alanazi S, Yuan L, Solomon T, Thaker TM, Jura N, Garrett JT. Oncotarget 9 27773-27788 (2018)
- Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects. Saul S, Karim M, Ghita L, Huang PT, Chiu W, Durán V, Lo CW, Kumar S, Bhalla N, Leyssen P, Alem F, Boghdeh NA, Tran DH, Cohen CA, Brown JA, Huie KE, Tindle C, Sibai M, Ye C, Khalil AM, Chiem K, Martinez-Sobrido L, Dye JM, Pinsky BA, Ghosh P, Das S, Solow-Cordero DE, Jin J, Wikswo JP, Jochmans D, Neyts J, De Jonghe S, Narayanan A, Einav S. J Clin Invest 133 e169510 (2023)
- Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. Ravichandran S, Luke BT, Collins JR. J. Mol. Graph. Model. 57 36-48 (2015)
- Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors. Sonar P, Shaikh K, Ballav S, Basu S, Harer S. Bioinformation 18 974-981 (2022)
- Design, Synthesis, ADME, and Anticancer Studies of Newer N-Aryl-5-(3,4,5-Trifluorophenyl)-1,3,4-Oxadiazol-2-Amines: An Insight into Experimental and Theoretical Investigations. Agarwal M, Afzal O, Salahuddin, Altamimi ASA, Alamri MA, Alossaimi MA, Sharma V, Ahsan MJ. ACS Omega 8 26837-26849 (2023)
- Inhibition of mutationally activated HER2. Collins SJ, Guo J, Rizzo RC, Miller WT. Chem Biol Drug Des 101 87-102 (2023)
- Interactome of ErbB4 unveiled. Takahashi TT, Li S. Chem. Biol. 15 753-754 (2008)
- Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer. McCorkle JR, Gorski JW, Liu J, Riggs MB, McDowell AB, Lin N, Wang C, Ueland FR, Kolesar JM. PLoS One 16 e0254205 (2021)
- Network-based approach for targeting human kinases commonly associated with amyotrophic lateral sclerosis and cancer. Khatoon F, Haque S, Hashem A, Mahmoud A, Tashkandi H, Mathkor D, Harakeh S, Alghamdi B, Kumar V. Front Mol Neurosci 15 1023286 (2022)
- Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N. Structure 26 270-281.e4 (2018)
- Structure and dynamics of the EGFR/HER2 heterodimer. Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, He K, Zhang Z. Cell Discov 9 18 (2023)
- Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. Ye M, Huang W, Liu R, Kong Y, Liu Y, Chen X, Xu J. Front Pharmacol 12 651516 (2021)